- Home
- TENB vs AUPH Comparison
TENB vs AUPH Comparison
Compare TENB & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TENB | AUPH |
|---|---|---|
| Founded | 2002 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TENB | AUPH |
|---|---|---|
| Price | $20.73 | $15.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 4 |
| Target Price | ★ $31.69 | $17.25 |
| AVG Volume (30 Days) | ★ 3.2M | 966.7K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.23 | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | ★ $999,405,000.00 | $283,055,000.00 |
| Revenue This Year | $9.37 | $17.54 |
| Revenue Next Year | $7.04 | $15.74 |
| P/E Ratio | ★ N/A | $7.42 |
| Revenue Growth | 11.04 | ★ 20.38 |
| 52 Week Low | $15.73 | $7.29 |
| 52 Week High | $35.69 | $16.88 |
Technical Indicators
Market Signals| Indicator | TENB | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 48.46 |
| Support Level | $19.15 | $14.56 |
| Resistance Level | $21.25 | $16.32 |
| Average True Range (ATR) | 1.13 | 0.50 |
| MACD | 0.33 | -0.11 |
| Stochastic Oscillator | 74.48 | 16.07 |
Price Performance
Historical ComparisonAbout TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.